US Edition
Breyanzi Demonstrates Promising Efficacy in Phase II TRANSCEND FL Trial for Relapsed Marginal Zone Lymphoma
Summary by healtheconomics.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Breyanzi Demonstrates Promising Efficacy in Phase II TRANSCEND FL Trial for Relapsed Marginal Zone Lymphoma
In the Phase II TRANSCEND FL trial, Breyanzi (lisocabtagene maraleucel) demonstrated significant efficacy in treating patients with relapsed or refractory marginal zone lymphoma (MZL). With a remarkable overall response rate of 95.5% and a complete response rate of 62.1%, Breyanzi shows promise as an effective treatment for this challenging condition. The trial, which is the largest of its kind evaluating chimeric antigen receptor (CAR) T-cell t…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
